{"id":539509,"date":"2025-10-31T09:10:12","date_gmt":"2025-10-31T09:10:12","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/539509\/"},"modified":"2025-10-31T09:10:12","modified_gmt":"2025-10-31T09:10:12","slug":"fda-reports-recall-of-blood-pressure-medication-containing-a-potential-carcinogen","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/539509\/","title":{"rendered":"FDA reports recall of blood pressure medication containing a potential carcinogen"},"content":{"rendered":"

The U.S. Food and Drug Administration says drug makers have recalled more than a half-million bottles of the blood pressure medication prazosin hydrochloride over concerns it may include a cancer-causing chemical. <\/p>\n

New Jersey-based Teva Pharmaceuticals USA and drugs distributor Amerisource Health Services issued voluntary nationwide recalls<\/a> earlier this month of more than 580,000 bottles of various strengths of prazosine capsules, according to the FDA. <\/p>\n

Doctors prescribe prazosin, which relaxes blood vessels, to help lower blood pressure. It also is sometimes prescribed for nightmares and other sleep disturbances caused by post-traumatic stress disorder. <\/p>\n

The FDA said in enforcement orders<\/a> posted online that it has given the affected lots of the drug a Class II risk classification because some of the recalled medication may have nitrosamine impurities that are considered potentially cancer causing. <\/p>\n

According to the FDA, N-nitrosamine impurities<\/a> are a class of potentially cancer-causing chemicals that can form during manufacture or storage of a drug.<\/p>\n","protected":false},"excerpt":{"rendered":"The U.S. Food and Drug Administration says drug makers have recalled more than a half-million bottles of the…\n","protected":false},"author":2,"featured_media":539510,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4315],"tags":[1204,173968,4179,105,4326,3236,6587,16,15,263],"class_list":{"0":"post-539509","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-medication","8":"tag-cancer","9":"tag-drug-recalls","10":"tag-general-news","11":"tag-health","12":"tag-medication","13":"tag-product-recalls","14":"tag-u-s-food-and-drug-administration","15":"tag-uk","16":"tag-united-kingdom","17":"tag-world-news"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/115468004562569343","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/539509","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=539509"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/539509\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/539510"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=539509"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=539509"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=539509"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}